Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03504423
Title Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Rafael Pharmaceuticals Inc.

pancreatic adenocarcinoma



CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin

Age Groups: adult | senior
Covered Countries USA | FRA | DEU | BEL

No variant requirements are available.